HAL (France)
open access
Optimizing nanobody-based molecules targeting mesothelin: Exploring format, valency, size, and half-life for next-generation cancer theranostics
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Advances in the design and discovery of small-molecule tyrosine kinase inhibitors for breast cancer.#395993
- Advancements in Cubosomes: A Promising Platform for Targeted Anticancer Drug Delivery#194517
- Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies#875062
- Human SFI1 and Centrin form a complex critical for centriole architecture and ciliogenesis#1066153
- Generative AI-Based Drug Design: Target-Aware Molecular Generation for EGFR Type I Inhibitors with Multiplatform Docking Validation.#338438
Record · ID 330076
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive